Clinical Trial Update: A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) [Phase 1, Phase 2]

View source ↗

Summary

A dose-escalation and cohort-expansion study of subcutaneously administered nemvaleukin alfa (ALKS 4230), alone and with pembrolizumab, in advanced/metastatic s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Nemvaleukin alfa (nemvaleukin alfa)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Mural Oncology, Inc | Conditions: Advanced Solid Tumors | Phase 1, Phase 2 | Status: COMPLETED